ABSTRACT
Objective:To study the morphology of hemophagocytosis (HPC) in bone marrow smears of patients with infection-associated hemophagocytic lymphohistiocytosis (IAHLH), and further analyse if there were differences in the clinical and laboratory features, the cytokines level and prognosisMethods:24 patients newly diagnosed with IAHLH from 2016-Dec-1 to 2021-Dec-31 in Beijing Friendship Hospital were included as study group, and 20 patients with infectious disease as non-HLH control group. In IAHLH group, mean age was 34±13 years, including 17(71%) males and7(29%) females. In Non-HLH group, mean agewas 43±16 years, including 14 (70%) males and6 (30%) females. Depending on re-checking phagocytic cell type on the initial bone marrow smear, the HPCs were divided into HPC-1, phagocytizing non-nucleated cells (mature erythrocyte or platelets), and HPC-2, phagocytizing nucleated cells. The differences in clinical presentations covered in HLH-2004 criteria, cytokines value(IL-6, IL-10, IL-18, IFN-γ) recommended in HLH-2022-China guideline, and the mortality within 1 year of diagnosis, were compared between IAHLH and non-HLH groups, between patients with or without HPC, and between patients with HPC-2 or only with HPC-1. For categorical variables, two groups were compared with the use of either the chi-square test or Fisher′s exact test. For non-normal distribution continuous variables, the difference between two groups variation was performed by using Mann-Whitney U test, and for normal distribution continuous variables, the difference was by the Independent Samples t-test.Results:The positive rates of fever, hepatomegaly and splenomegalyand the motrtality in IAHLH were 100% (24/24), 63% (15/24), 92% (22/24) and 46% (11/24), respectivelyin non-HLH were 55%(11/20),0(0/20),25% (5/20),0(0/20),and the differences between two groups were all statistically significant( P<0.01), but thedifferences between groups with and without HPC and between IAHLH patients with HPC-2 or only with HPC-1 were no statistically significanlly, ( P>0.05).In IAHLH group, IFN-γ in patients with HPC-2 was 400(246, 532)ng/L, significantly higher than 146(38, 180)ng/L in patients only with HPC-1 [ P=0.02, 95% CI was 233(75.8 to 397)], andthe other test parameters and cytokines level showed no obvious differences ( P>0.05).
ABSTRACT
BACKGROUND@#Small cell lung cancer (SCLC) is highly malignant and prone to bone marrow metastasis in early stage, but its related reports are limited. This study analyzed the clinical feature, laboratory examination, treatment and prognosis of SCLC patients with bone marrow metastasis.@*METHODS@#The clinical data of 26 SCLC patients with bone marrow metastasis were analyzed retrospectively. Prognostic factors were evaluated.@*RESULTS@#The median age of 26 patients was 57 years and the median time from diagnosis of SCLC to confirmed bone marrow metastases was 8 d. Most patients (96.2%) were accompanied by other organ metastases. The most common laboratory abnormalities were elevated lactate dehydrogenase in 19 cases (73.1%), thrombocytopenia and elevated alkaline phosphatase respectively in 11 cases (42.3%) and anemia in 7 cases (26.9%). Twenty patients had received chemotherapy and the remaining 6 patients had not. Of this group, 16 patients received at least 2 cycles of chemotherapy after the diagnosis of bone marrow metastasis. The median survival time was 15.7 wk (0.1 wk-82.9 wk) after diagnosis of bone marrow metastasis. The survival of patients with chemotherapy was significantly better than that of those without chemotherapy (χ²=33.768, P<0.001). Multivariate analysis showed that no chemotherapy was independent poor prognostic factors (P<0.05).@*CONCLUSIONS@#The SCLC patients with bone marrow metastasis have short survival, whereas chemotherapy can extend the survival of patients.
Subject(s)
Aged , Female , Humans , Male , Middle Aged , Bone Marrow , Pathology , Bone Marrow Neoplasms , Mortality , Pathology , Lung Neoplasms , Pathology , Neoplasm Metastasis , Retrospective Studies , Small Cell Lung Carcinoma , PathologyABSTRACT
Objective To investigate the application of Multi-tumor markers Protein Chip Diagnose System in the diagnosing of ovarian cancer. Methods Using the Multi-tumor markers Protein Chip Diagnose System to determine and analyze the concentration values of 12 tumor markers(AFP, CEA, NSE, CA125, CA153, CA242, CA199, PSA, f-PSA, FER, ?-HCG and HGH) in the sera of 53 malignant ovarian cancer patients, 12 ovarian cysts patients and 98 normal persons. Result At least one kind of tumor marker was found higher in 44 sera of the 53 malignant ovarian cancer patients(positive ratio is 83 0%), in 7 sera of the 12 ovarian cysts patients(positive ratio is 58 3%) and 2 sera of the 98 normal persons (negative ratio is 97 9%). NSE、HGH、PSA and f-PSA were first found higher in the sera of ovarian cancer patients. Conclusion The application of Multi-tumor markers Protein Chip Diagnose System in the diagnosing of cancer not only greatly reduces analysis of tumor markers concentration in serum and left the accuracy of diagnosis but may lead new discoveries about the tumor markers.